System and methods for performing saliva-based diagnostic screenings
US-2024420847-A1 · Dec 19, 2024 · US
US10094833B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10094833-B2 |
| Application number | US-201515502711-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 6, 2015 |
| Priority date | Aug 8, 2014 |
| Publication date | Oct 9, 2018 |
| Grant date | Oct 9, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to a novel antibody which binds to C-SLPI selected from the group consisting of SEQ ID NOs: 3 and 4.
Opening claim text (preview).
We claim: 1. An immunogen comprising a polypeptide hapten of 5-12 amino acids in length comprising the structure Gln-Cys-Leu-Arg (SEQ ID NO: 10), wherein the N-terminus region of the polypeptide hapten comprises SEQ ID NO: 10; and wherein the polypeptide hapten is linked to an immunogenicity conferring carrier molecule by the C-terminal amino acid of the polypeptide hapten. 2. An antibody, or antigen binding fragment thereof, that is capable of specifically binding, to an epitope of C-terminal peptide fragment of Secretory leukocyte protease inhibitor (C-SLPI), the peptide fragment which is 10, 11 or 12 amino acids in length and comprises SEQ ID NO: 6 wherein the N-terminus region of the polypeptide fragment comprises SEQ ID NO: 6 and wherein the cross-reactivity of the antibody with full-length SLPI is <0.05%. 3. A method of determining an individual's C-SLPI level by: (a) contacting an antibody specific for C-terminal fragment of Secretory leukocyte protease inhibitor (C-SLPI) with a sample from the individual; and (b) detecting the amount of C-terminal fragment of Secretory leukocyte protease inhibitor (C-SLPI) in the sample; wherein the cross-reactivity of the antibody with full-length Secretory leukocyte protease inhibitor (SLPI) is <0.05%.
against enzymes · CPC title
for enzymes or isoenzymes · CPC title
with the first amino acid being acidic · CPC title
from mammals · CPC title
Infectious diseases, e.g. generalised sepsis · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.